These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38841182)

  • 1. Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.
    Smaoui H; Chtourou L; Jallouli D; Jemaa SB; Karaa I; Boudabbous M; Moalla M; Gdoura H; Mnif L; Amouri A; Akrout R; Ayadi F; Baklouti S; Tahri N
    Future Sci OA; 2024; 10(1):FSO977. PubMed ID: 38841182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength.
    Hussain MS; Mazumder T
    J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):567-579. PubMed ID: 34687598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors.
    Shin YH; Gong HS; Baek GH
    J Clin Densitom; 2019; 22(2):236-242. PubMed ID: 30100220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term proton pump inhibitors on bone mineral density.
    Romdhane H; Ayadi S; Elleuch N; Abdelghani K
    Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
    Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
    Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density.
    Fattahi MR; Niknam R; Shams M; Anushiravani A; Taghavi SA; Omrani GR; Mahmoudi L
    Risk Manag Healthc Policy; 2019; 12():349-355. PubMed ID: 31853206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of proton pump inhibitors on bone mineral density: A systematic review and meta-analysis of observational studies.
    Aleraij S; Alhowti S; Ferwana M; Abdulmajeed I
    Bone Rep; 2020 Dec; 13():100732. PubMed ID: 33299906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged Use of Proton Pump Inhibitors, but Not Histamine-2 Receptor Antagonists, Is Associated With Lower Bone Mineral Density in Males Aged Over 70.
    Gao S; Song W; Lin T; Chen W; He W; Wei Q; Li Z
    Front Med (Lausanne); 2021; 8():725359. PubMed ID: 34497815
    [No Abstract]   [Full Text] [Related]  

  • 10. A survey on the incidence of common musculoskeletal side effects among the patients taking long-term anti-ulcerant therapies in Bangladesh.
    Mitra S; Hussain MS; Rahman R; Salam MA; Mazumder T; Farzana S
    Toxicol Rep; 2022; 9():1796-1805. PubMed ID: 36518456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors, bone and phosphocalcic metabolism.
    Philippoteaux C; Paccou J; Chazard E; Cortet B
    Joint Bone Spine; 2024 Mar; 91(5):105714. PubMed ID: 38458487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
    Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
    J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?
    Ben-Eltriki M; Chhabra M; Cassels A; Wright JM
    Curr Drug Saf; 2024; 19(2):244-247. PubMed ID: 37496243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
    Lau YT; Ahmed NN
    Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?
    Luk CP; Parsons R; Lee YP; Hughes JD
    Ann Pharmacother; 2013 Jun; 47(6):773-80. PubMed ID: 23632281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent Association Between Use of Proton Pump Inhibitors and Muscle Wasting in Patients with Heart Failure: A Single-Center, Ambispective, Observational Study.
    Ohori K; Yano T; Katano S; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Kouzu H; Koyama M; Nagano N; Fujito T; Nishikawa R; Ohwada W; Furuhashi M
    Drugs Aging; 2023 Aug; 40(8):731-739. PubMed ID: 37328671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients.
    Recart DA; Ferraris A; Petriglieri CI; Alonso Serena M; Bonella MB; Posadas-Martinez ML
    Intern Emerg Med; 2021 Apr; 16(3):711-717. PubMed ID: 33001349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary hyperparathyroidism: Predictors and relationship with vitamin D status, bone turnover markers and bone mineral density.
    Fitzpatrick D; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; Healy M; Molloy AM; McNulty H; Lannon R; McCarroll K
    Bone; 2024 Jul; 184():117108. PubMed ID: 38642819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
    Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
    J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitor therapy and potential long-term harm.
    Corleto VD; Festa S; Di Giulio E; Annibale B
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):3-8. PubMed ID: 24310148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.